Latest News

14 March 2019

The world-wide number of pre-clinical drugs under development over 2017-2018 increased from 7493 to 8040, a whopping 7.3% (1). The largest class of these drugs, synthetic chemicals, increased from 7855 to 7992 throughout the same period. The second largest, antibody drugs, similarly showed considerable growth from 1687 to 1809 (7.2%). Overall the largest therapeutic class, […]

11 March 2019

As the company continues to expand we have purchased additional laboratory equipment to enable us to continue to efficiently deliver for our customers. Recently we have installed an analytical LCMS,  preparative HPLC system (pictured below) and a freeze dryer. This additional equipment has increased productivity on our medicinal chemistry projects which is great news for […]

01 March 2019

Apex Molecular appointed Mark Warburton as a Non-executive Director on 1 December 2018. Mark’s experience as a corporate finance/banking lawyer and as COO of Cyprotex Discovery will add significantly to the corporate governance and commercial activities of the Company in the coming years of the Company’s growth and development.

25 January 2019

One of the country’s fastest growing specialist contract research organisations has today unveiled a new name and brand. Apex Molecular, formerly YProtech, is a provider of synthetic chemistry services and operates from a base at Alderley Park in Cheshire. The rise of contract research organisations (CROs) is a marked trend in drug discovery, with Apex […]

04 May 2018

YProtech will be attending the 8th RSC/SCI symposium on kinases in Cambridge on 14th-15th May which will encompass case studies of ongoing programmes as well as successful past programmes. A range of topics including CNS kinase inhibitors, allosteric inhibitors and non-oral delivery methods will be covered, along with views and perspectives on the future of […]

03 May 2018

Dr Kelvin Ho joins YProtech as a Research Chemist. An experienced Medicinal Chemist, Kelvin previously worked for several years with a UK based Drug Discovery company. Kelvin’s appointment further strengthens our Medicinal Chemistry expertise and offering to the market.

Make an enquiry

Send us your details, and one of
our expert team will be in touch